Bio tanker.ECYT Endocyte falls as vintafolide monotherapy unlikely to show NSCLC PFS superiority Endocyte (ECYT) plummets as the DSMB for TARGET advises investigators and patients that vintafolide monotherapy is not likely to be declared superior in PFS to docetaxel.The Phase 2b trial had two arms, vintafolide monotherapy and vintafolide in combination with docetaxel, which were to be compared with standard of care (docetaxel monotherapy).The DSMB did recommend the continuation of the combination therapy arm.Top-line results are due early next year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.